Epigenetic clocks aid population aging research but not individual health decisions
Updated
Updated · The Conversation · May 4
Epigenetic clocks aid population aging research but not individual health decisions
10 articles · Updated · The Conversation · May 4
Researchers say consumer biological-age tests costing about $30 to more than $1,000 can give inconsistent individual results across different clocks, sample types and even testing times.
They say short-term changes in diet, illness, environment and time of day can alter readings, while no gold-standard method exists across laboratories or technologies.
The tools remain useful for studying groups, linking habits and treatments such as rapamycin to slower aging, but individual use could mislead consumers and worsen insurance or health disparities.
Biological age tests are a booming billion-dollar market. Why do leading scientists warn they are unreliable for personal health decisions?
If your epigenetic clock can reflect past trauma, what are the ethical risks of using it for insurance or employment?
Epigenetic Clocks in 2026: Scientific Shortcomings, Ethical Minefields, and the Path to Clinical Utility
Overview
Recent studies, including the MACRO trial, reveal that improvements in metabolic health from weight loss do not correspond with changes in current epigenetic aging clocks, challenging their use as short-term markers of biological aging. Experts suggest these clocks conflate harmful aging signals with the body's adaptive responses, causing misleading results. Additionally, epigenetic clocks face issues like measurement noise, genetic and demographic biases, and limited clinical utility, especially for individual healthspan predictions. Ethical concerns arise from their misuse and lack of transparency. Advances in next-generation clocks focusing on causal mechanisms, noise reduction, and multi-omics integration offer promise, but regulatory validation remains a key hurdle before clinical adoption.